BTIG analyst Sean Lavin upgraded ABIOMED (NASDAQ: ABMD) from Neutral to Buy with a price target of $450.00.The analyst comments ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE